Dostarlimab achieves durable complete clinical responses in dMMR/MSI-H locally advanced rectal cancer

Share :
Published: 26 Oct 2026
Views: 78
Rating:
Save
Dr Meredith Pelster - Sarah Cannon Research Institute, Nashville, USA

Dr Meredith Pelster speaks to ecancer about the first results from the global registrational AZUR-1 trial, which evaluated dostarlimab monotherapy in patients with mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) locally advanced rectal cancer.

This patient population can be particularly responsive to PD-1 blockade, potentially avoiding the need for standard treatment with chemotherapy, radiotherapy and surgery.

Among 144 patients with at least 12 months of follow-up, 68% achieved a sustained clinical complete response for at least 12 months after treatment, as assessed by investigators.

The combined rate of sustained clinical complete response or pathological complete response was 76%.

No recurrences have been reported to date among patients achieving a clinical or pathological complete response, and 71% of all enrolled patients remained under surveillance with no evidence of disease progression after dostarlimab alone.

Dr Pelster says the treatment was generally well tolerated, with grade 3 or higher immune-mediated adverse events reported in four patients.

These findings highlight the potential of dostarlimab to offer a chemotherapy, radiotherapy and surgery-free treatment approach for selected patients with dMMR/MSI-H rectal cancer.

Related Videos

Early ctDNA clearance linked to improved outcomes in KRAS G12C-mutant colorectal cancer

Dr Filippo Pietrantonio - Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
Early ctDNA clearance linked to improved outcomes in KRAS G12C-mutant colorectal cancer ( Dr Filippo Pietrantonio - Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy )
10 Jun 2026

Early-onset gastrointestinal cancers show more advanced disease and wider racial survival gaps

Dr Jessica Paulus - Ontada, Boston, USA
Early-onset gastrointestinal cancers show more advanced disease and wider racial survival gaps ( Dr Jessica Paulus - Ontada, Boston, USA )
1 Jun 2026

Tarlatamab improves brain metastases control and survival compared to chemo in SCLC

Dr Giannis Mountzios - The University of Athens, Athens, Greece
Tarlatamab improves brain metastases control and survival compared to chemo in SCLC ( Dr Giannis Mountzios - The University of Athens, Athens, Greece )
1 Jun 2026

Trastuzumab and tucatinib enable organ preservation in HER2-positive rectal cancer

Dr Michael Foote - Memorial Sloan Kettering Cancer Cente, New York City, USA
Trastuzumab and tucatinib enable organ preservation in HER2-positive rectal cancer ( Dr Michael Foote - Memorial Sloan Kettering Cancer Cente, New York City, USA )
23 Apr 2026

Zolbetuximab plus nivolumab and chemotherapy shows promising responses in CLDN18.2-positive metastatic gastric cancer

Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan
Zolbetuximab plus nivolumab and chemotherapy shows promising responses in CLDN18.2-positive metastatic gastric cancer ( Dr Kohei Shitara - National Cancer Center Hospital East, Kashiwa, Japan )
23 Mar 2026

Physical activity reduces fatigue and improves quality of life in colorectal cancer survivors

Dr Louisa Liu - Cedars-Sinai Medical Center, Los Angeles, USA
Physical activity reduces fatigue and improves quality of life in colorectal cancer survivors ( Dr Louisa Liu - Cedars-Sinai Medical Center, Los Angeles, USA )
15 Jan 2026

Zanidatamab improves PFS and OS in first-line HER2-positive metastatic gastric cancer

Dr Elena Elimova - The Princess Margaret Hospital, Toronto, Canada
Zanidatamab improves PFS and OS in first-line HER2-positive metastatic gastric cancer ( Dr Elena Elimova - The Princess Margaret Hospital, Toronto, Canada )
15 Jan 2026

Consolidation treatment delays do not compromise survival in MRD-negative adult ALL

Prof Bhavana Bhatnagar - WVU Medicine Wheeling Hospital, Wheeling, USA
Consolidation treatment delays do not compromise survival in MRD-negative adult ALL ( Prof Bhavana Bhatnagar - WVU Medicine Wheeling Hospital, Wheeling, USA )
7 Jan 2026

Addition of trastuzumab to chemo does not provide significant survival benefit in HER-2 positive stomach cancer

Dr Anna Dorothea Wagner - Lausanne University Hospital, Lausanne, Switzerland
Addition of trastuzumab to chemo does not provide significant survival benefit in HER-2 positive stomach cancer ( Dr Anna Dorothea Wagner - Lausanne University Hospital, Lausanne, Switzerland )
21 Feb 2025